Quality Reforms, Biopharma Ecosystem Top Priority to Keep India as ‘Pharmacy of World’: Pharma Secy Manoj Joshi

Following concerns over substandard medicines and scrutiny of Indian drug exports, what reforms has the government undertaken to strengthen manufacturing quality and regulatory oversight? The revised Schedule M became mandatory from January 1. Companies that do not comply with the revised WHO-GMP standards are being asked to shut down unless they are in the process of upgrading. Other measures include stricter regulation of exports, requiring regulatory No Objection Certificates (NOCs) for certain products not sold domestically. Revised Schedule M also prevents non-compliant companies from participating in government tenders. Looking ahead, what do you see as the three biggest challenges for…